Posicionamento da ASBAI sobre a vacinação
de crianças de 5 a 11 anos contra a COVID-19
com a vacina Comirnaty/ Pfizer/BioNTech – 27/12/2021

Ana Karolina Barreto Berselli Marinho; Lorena de Castro Diniz; Bianca Noleto Ayres Guimarães; Clarissa Morais Busatto Gerhardt; Cláudia França Cavalcante Valente; Claudia Leiko Yonekura Anagusko; Fátima Rodrigues Fernandes; Gisele Feitosa Zuvanov Casado; Mônica de Araújo Álvares da Silva; Newton Bellesi; Ronney Correa Mendes; Dewton de Moraes Vasconcelos; Ekaterini Simões Goudouris; Pedro Giavina-Bianchi; Emanuel Savio Cavalcanti Sarinho

doi:10.5935/2526-5393.20220004

Special Article

Posicionamento da ASBAI sobre a vacinação de crianças de 5 a 11 anos contra a COVID-19 com a vacina Comirnaty/ Pfizer/BioNTech – 27/12/2021

ASBAI's position on vaccination of children aged 5 to 11 years against COVID-19 with the Comirnaty/Pfizer/BioNTech vaccine – 12/27/2021

Ana Karolina Barreto Berselli Marinho; Lorena de Castro Diniz; Bianca Noleto Ayres Guimarães; Clarissa Morais Busatto Gerhardt; Cláudia França Cavalcante Valente; Claudia Leiko Yonekura Anagusko; Fátima Rodrigues Fernandes; Gisele Feitosa Zuvanov Casado; Mônica de Araújo Álvares da Silva; Newton Bellesi; Ronney Correa Mendes; Dewton de Moraes Vasconcelos; Ekaterini Simões Goudouris; Pedro Giavina-Bianchi; Emanuel Savio Cavalcanti Sarinho

http://dx.doi.org/10.5935/2526-5393.20220004 Arq Asma Alerg Imunol, vol.6, n1, p.58-62, 2022

PDF

Downloads: 0

Resumo

A Associação Brasileira de Alergia e Imunologia (ASBAI) se manifesta totalmente favorável à imunização contra a COVID-19 em indivíduos entre 5 e 11 anos, para a proteção não somente deste grupo, mas também de seus conviventes. A vacinação de crianças, demonstrada sua eficácia e segurança, é fundamental para o controle da circulação do vírus e proteção de indivíduos cuja resposta vacinal pode não ocorrer de modo eficiente, como os imunocomprometidos e idosos. A imunização de pessoas entre 5 e 11 anos deve ser uma estratégia de saúde pública fundamental para o controle da pandemia que nos assola desde março de 2020 com todas as suas graves consequências para a saúde pública e a economia.

Palavras-chave

Vacinas contra COVID-19, imunização, criança.

Abstract

The Brazilian Association of Allergy and Immunology (ASBAI) is totally in favor of immunization against COVID-19 in individuals between 5 and 11 years old, for the protection not only of this group, but also of their cohabitants. The vaccination of children, once its efficacy and safety has been demonstrated, is essential for controlling the circulation of the virus and protecting individuals whose vaccine response may not occur efficiently, such as the immunocompromised and the elderly. The immunization of people between the ages of 5 and 11 must be a fundamental public health strategy to control the pandemic that has been plaguing us since March 2020 with all its serious consequences for public health and the economy.

Keywords

COVID-19 vaccines, immunization, child.

References

1. FIOCRUZ. COVID-19 e Saúde da Criança e do Adolescente [site na Internet]. Disponível em: https://portaldeboaspraticas.iff.fiocruz.br/wp-content/uploads/2021/09/Covid_edu_v2.pdf. Acessado em: 22/12/2021.

2. FIOCRUZ. Fiocruz analisa dados sobre mortes de crianças por Covid-19 [site na Internet]. Disponível em: https://portal.fiocruz.br/noticia/fiocruz-analisa-dados-sobre-mortes-de-criancas-por-covid-19. Acessado em: 23/12/2021.

3. Brasil. Ministério da Saúde. Boletim Epidemiológico Especial - Doença pelo Novo Coronavírus - COVID-19. Semana epidemiológica 45: 7/11 a 13/11/2021. Disponível em: https://www.gov.br/saude/pt-br/centrais-de-conteudo/publicacoes/boletins/boletins-epidemiologicos/covid-19/2021/boletim_epidemiologico_covid_89_23nov21_fig37nv.pdf. Acessado em: 23/12/2021.

4. World Health Organization - WHO. Coronavirus disease (COVID-19): Post COVID-19 condition [site na Internet]. Disponível em: https://www.who.int/news-room/questions-and-answers/item/coronavirus-disease-(covid-19)-post-covid-19-condition.

5. Hageman JR. Long COVID-19 or Post-Acute Sequelae of SARS-CoV-2 Infection in Children, Adolescents, and Young Adults. Pediatr Ann. 2021 Jun;50(6):e232-e233.

6. Yahoo!notícias. Queiroga diz que mortes de crianças por covid "estão dentro de patamar aceitável" [site na Internet]. Disponível em: https://br.yahoo.com/noticias/queiroga-diz-que-mortes-de-criancas-por-covid-estao-dentro-de-patamar-aceitavel-171221199.html. Acessado em: 23/12/2021.

7. World Health Organization - WHO [site na Internet]. Global surveillance for COVID-19 caused by human infection with COVID-19 virus. Disponível em: https://www.who.int/publications/i/item/global-surveillance-for-covid-19-caused-by-human-infection-with-covid-19-virus-interim-guidance. Acessado em: 23/12/2021.

8. United States Food and Drug Administration - FDA. Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers) [Internet]. Disponível em: https://www.fda.gov/media/144413/download.

9. United States Food and Drug Administration - FDA. Pfizer-BioNTech COVID-19 Vaccine. Disponível em: https://www.fda.gov/emergency-preparednessandresponse/coronavirus-disease-2019-covid-19/pfizer-biontech-covid-19-vaccine.

10. Interim Report - Children 5 to <12 Years of Age: A Phase 1, Open-Label Dose-Finding Study to Evaluate Safety, Tolerability, and Immunogenicity and Phase 2/3 Placebo-Controlled, Observer-Blinded Safety, Tolerability, and Immunogenicity Study of a SARS-CoV-2 RNA Vaccine Candidate Against COVID-19 In Healthy Children and Young Adults Número de Protocolo: C4591007.

11. Su JR; Vaccine Safety Team; CDC COVID-19 Vaccine Task Force. Adverse events among children ages 5-11 years after COVID-19 vaccination: updates from v-safe and the Vaccine Adverse Event Reporting System (VAERS) - Dec 13, 2021 [Internet].

12. Pfizer.com [site na Internet]. Pfizer and Biontech provide update on ongoing studies of Covid-19 Vaccine. Disponível em: www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-provide-update-ongoing-studies-covid-19. Acessado em: 23/12/2021.

13. McNeil MM, Weintraub ES, Duffy J, Sukumaran L, Jacobsen SJ, Klein NP, et al. Risk of anaphylaxis after vaccination in children and adults. J Allergy Clin Immunol. 2016;137:868-78.

14. Woodworth KR, Moulia D, Collins JP, Hadler SC, Jones JM, Reddy SC, et al. The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Children Aged 5-11 Years - United States, November 2021. MMWR Morb Mortal Wkly Rep. 2021 Nov 12;70(45):1579-83. doi: 10.15585/mmwr.mm7045e1.

15. Olson SM, Newhams MM, Halasa NB, Price AM, Boom JA, Sahni LC, et al.; Overcoming COVID-19 Investigators. Effectiveness of Pfizer-BioNTech mRNA Vaccination Against COVID-19 Hospitalization Among Persons Aged 12-18 Years - United States, June-September 2021. MMWR Morb Mortal Wkly Rep. 2021 Oct 22;70(42):1483-8. doi: 10.15585/mmwr.mm7042e1.

16. Moss WJ, Gostin LO, Nuzzo JB. Pediatric COVID-19 Vaccines: What Parents, Practitioners, and Policy Makers Need to Know. JAMA. 2021 Dec 14;326(22):2257-8. doi: 10.1001/jama.2021.20734.

17. Zou X, Cao B. COVID-19 vaccines for children younger than 12 years: are we ready? Lancet Infect Dis. 2021 Dec;21(12):1614-5. doi: 10.1016/S1473-3099(21)00384-4.

18. Saxena S, Skirrow H, Wighton K. Should the UK vaccinate children and adolescents against covid-19? BMJ. 2021;374:n1866. doi: 10.1136/bmj.n1866.

19. United States Food and Drug Administration - FDA. FDA Authorizes Pfizer-BioNTech COVID-19 vaccine for emergency use in children 5 through 11 years of age [site na Internet]. Disponível em: https://www.fda.gov/news-events/press-announcements/fda-authorizes-pfizer-biontech-covid-19-vaccine-emergency-use-children-5-through-11-years-age. Acessado em: 18/12/2021.

20. Government of Canada - Health Canada. Vaccines for children: COVID-19 [site na Internet]. Disponível em: https://www.canada.ca/en/public-health/services/vaccination-children/covid-19.html. Acessado em: 18/12/2021.

21. European Medicines Agency - EMA. Comirnaty COVID-19 vaccine: EMA recommends approval for children aged 5 to 11 [site na Internet]. Disponível em: https://www.ema.europa.eu/en/news/comirnaty-covid-19-vaccine-ema-recommends-approval-children-aged-5-11. Acessado em: 22/12/2021.

22. Australian Government - Department of Health. TGA provisionally approves Pfizer COVID-19 vaccine for 5 to 11 years-olds [site na Internet]. Disponível em: https://www.health.gov.au/news/tga-provisionally-approves-pfizer-covid-19-vaccine-for-5-to-11-year-olds. Acessado em: 22/12/2021.

23. Government of Singapore - Health Sciences Authority - HSA. HSA extends the use of comirnaty COVID-19 vaccine by Pfizer-BioNTech to children of ages 5 to 11 [site na Internet]. Disponível em: https://www.hsa.gov.sg/announcements/press-release/pfizercomirnaty_children. Acessado em: 22/12/2021.

24. Swissmedic - Swiss Agency for Therapeutic Products. Swissmedic approves COVID-19 vaccine from Pfizer/BioNTech for children aged 5 to 11 years [site na Internet]. Disponível em: https://www.swissmedic.ch/swissmedic/en/home/news/coronavirus-covid-19/covid-19-impfstoff-pfizer-biontec-kinder-5-11-jahren-genehmigt.html. Acessado em 23/12/2021.

25. GOV.UK. UK regulator approves use of Pfizer/BioNTech vaccine in 5- to 11-year-olds [site na Internet]. Disponível em: https://www.gov.uk/government/news/uk-regulator-approves-use-of-pfizerbiontech-vaccine-in-5-to-11-year-olds#:~:text=A%20new%20age%2Dappropriate%20formulation,it%20is%20safe%20and%20effective. Acessado em: 23/12/2021.

26. ANVISA - GGMED. Parecer Público de Avaliação do Medicamento - Aprovação [site na Internet]. Disponível em: https://www.gov.br/anvisa/pt-br/assuntos/noticias-anvisa/2021/copy_of_PPAM511anosPfizer2.pdf. Acessado em: 23/12/2021.

Submitted date:
01/18/2021

Accepted date:
01/25/2021